Filing Details
- Accession Number:
- 0001209191-21-063698
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-09 18:08:44
- Reporting Period:
- 2021-11-05
- Accepted Time:
- 2021-11-09 18:08:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1652130 | Intellia Therapeutics Inc. | NTLA | In Vitro & In Vivo Diagnostic Substances (2835) | 364785571 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1810882 | David Lebwohl | C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139 | Evp, Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-05 | 2,400 | $12.62 | 11,114 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-05 | 1,200 | $131.71 | 9,914 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-05 | 452 | $132.62 | 9,462 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-05 | 548 | $134.07 | 8,914 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-05 | 200 | $135.34 | 8,714 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-11-05 | 2,400 | $0.00 | 2,400 | $12.62 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 180,077 | 2030-04-30 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.36 to $132.055, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.32, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.79 to $134.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 5, 2021 at each separate price.
- The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 75,000 shares as of November 5, 2021.
Billionaire Hedge Funds
